recombinantHAvaccinethusprovideanumberofbenefitsinvaccineperformancewhichcanbeextendedtootherviraltarget
reactionstothesecomponentsinsusceptibleindividualswiththeuseofRIV4.Thesedistinctstructuralfeaturesandpurityofth
eggproteins,viralRNAorprocessimpurities,typicallyfoundinconventionalvaccines,areexpectedtoeliminatepotentialadver
antibodieswithrarespecificitiesobservedwithRIV4.Furthermore,thepresenceofuniformcompactHAoligomersandabsence
certainconservedepitopesonHAmolecules,whicharelikelyresponsibleforthehighlevelsofbroadlycross-reactiveandprotecti
structuralfeatures.Theabsenceofprotease-drivencleavageandadditionofsimpleN-linkedglycanshelptopreserveandexpo